Lisdexamfetamine

Elite Pharmaceuticals, Inc. launched its generic version of Vyvanse® for ADHD treatment, available in various strengths. The product, marketed under Elite Laboratories, Inc., follows IQVIA's report of $4.3 billion in annual sales ending October 2024.

Elite Pharmaceuticals receives FDA approval for a generic version of Vyvanse® (Lisdexamfetamine Dimesylate) capsules, indicated for ADHD treatment.

Elite Pharmaceuticals receives FDA approval for generic Vyvanse, indicated for ADHD treatment.

Biosimilars, nearly identical to original biologics, are revolutionizing the pharma industry by offering significant cost savings, with U.S. healthcare projected to save billions. Despite regulatory hurdles and a need for greater education among patients and providers, the biosimilar market is rapidly expanding globally, driven by patent expirations and supportive policies.

Takeda Pharmaceutical reports 5% revenue growth in H1 FY24, driven by Growth & Launch portfolio, despite VYVANSE sales decline. The company raises full-year guidance, with core operating profit margin at 30.2%, and focuses on late-stage pipeline investments. Key highlights include ENTYVIO's double-digit growth and Phase 3 trials for TAK-861 and mezagitamab.

Takeda announced FY2024 H1 results with +13.4% revenue growth at AER and +5.0% at CER, driven by Growth & Launch Products (+18.7% at CER). Core Operating Profit increased +12.9% at CER, with a margin of 30.2%. ENTYVIO® revenue grew double-digits at CER, and geographical expansions included ADZYNMA® in EU and FRUZAQLA® in Japan. A Phase 3 trial for TAK-861 in narcolepsy type 1 started, and an R&D Day is scheduled for December 12 (EST) / 13 (JST). The company upgraded FY2024 forecasts due to stronger-than-expected H1 performance and revised FX assumptions.

6% of U.S. adults have ADHD; 71.5% of those on stimulant meds face difficulties due to drug shortages, impacting treatment and increasing risks.